References
- Adachi S, Ogasawara T, Wakimoto E et al (2001). Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma. Cancer, 91, 74-9. https://doi.org/10.1002/1097-0142(20010101)91:1<74::AID-CNCR10>3.0.CO;2-6
- Brabec V, Kasparkova J (2002). Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Update, 5, 147-61. https://doi.org/10.1016/S1368-7646(02)00047-X
- Chou TC (2007). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 59, 621-81.
- Kim R, Minami K, Nishimoto N, et al (2001). Enhancement of antitumor effect by ntratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol, 18, 363-7.
- Koshiyama M, Kinezaki M, Uchida T, Sumitomo M (2005). Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res, 25, 4499-502.
- Kunihiko K, Shoji K, Toshihiko T, et al(1995). In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve. J Cancer Res Clin Oncol, 121, 715-20. https://doi.org/10.1007/BF01213317
- Li S, Wang L, Lin Y, et al (2008). Reduction Nedaplatin combined with cisplatin as first-line therapy treat advanced esophageal carcinoma. Tumour, 28, 446-9.
- Liu W, Li S, Huang X, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
- Nial JW, Shonagh W, Gemma E, et al (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans, 39, 8113-27. https://doi.org/10.1039/c0dt00292e
- Nishida M, Satoh Y, Nishide K, et al (1999). Phase I study of a combination chemotherapy of nedaplatin and cisplatin. Gan To Kagaku Ryoho, 26, 2209-15.
- Pasetto LM, D'Andrea MR, Brandes AA, et al (2006). The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol, 60, 59-75. https://doi.org/10.1016/j.critrevonc.2006.02.003
- Risa T, Yasushi T, Yoshihiro S, et al (2005). In vitro sequencedependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol, 56, 279-85. https://doi.org/10.1007/s00280-004-0991-y
- Taguchi T, Wakui A, Nabeya K, et al (1992). A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother, 19, 483-8.
- Takeuchi H, Ozawa S, Ando N, et al (2003). Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol, 10, 792-800. https://doi.org/10.1245/ASO.2003.10.014
- Takeki U, Jyoji Y, Mikinori T, et al (2011). Comparative nephrotoxicity of cisplatin and nedaplatin:mechanisms and histopathological characteristics. Toxicol Pathol, 24, 87-94. https://doi.org/10.1293/tox.24.87
- Tanaka R, Takii Y, Shibata Y, et al (2005). In vitro sequencedependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol, 56, 279-85. https://doi.org/10.1007/s00280-004-0991-y
- Uehara T, Watanabe, Itoh F, et al (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol, 79, 451-60. https://doi.org/10.1007/s00204-005-0648-6
- Yao X, Panichpisal K, Kurtzman N, et al (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci, 334, 115-24. https://doi.org/10.1097/MAJ.0b013e31812dfe1e
Cited by
- Expression of bcl-2 and p53 in Induction of Esophageal Cancer Cell Apoptosis by ECRG2 in Combination with Cisplatin vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1397
- 顺铂联合热处理对术中回收血红细胞及其中混杂的肝肿瘤细胞株 (HepG2) 的影响 vol.16, pp.5, 2015, https://doi.org/10.1631/jzus.B1400224
- A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors vol.6, pp.1, 2016, https://doi.org/10.1038/srep36670
- MicroRNA and target mRNA selection through invasion and cytotoxicity cell modeling and bioinformatics approaches in esophageal squamous cell carcinoma vol.38, pp.2, 2017, https://doi.org/10.3892/or.2017.5776
- Apoptotic effects of ε-viniferin in combination with cis-platin in C6 cells vol.70, pp.3, 2018, https://doi.org/10.1007/s10616-018-0197-5
- Chemoresistance to Cancer Treatment: Benzo-α-Pyrene as Friend or Foe? vol.23, pp.4, 2018, https://doi.org/10.3390/molecules23040930